ACell, which makes surgical soft tissue implants for wounds and hernia repair, withdrew its plans for an initial public offering on Tuesday after postponing earlier this month. It had filed to raise $75 million by offering 5 million shares at a price range of $14 to $16.
The Columbia, MD-based company was founded in 1999 and booked $100 million in revenue for the 12 months ended March 31, 2020. It had planned to list on the Nasdaq under the symbol ACLL. UBS Investment Bank, Barclays, RBC Capital Markets and SunTrust Robinson Humphrey were set to be the joint bookrunners on the deal.
